Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

In regions where few people have received Covid-19 vaccines, health systems remain vulnerable to surges in SARS-CoV-2 infections. During the delta-wave of COVID-19 in India, for example, healthcare facilities and staff across the country struggled to cope with the surge in the number of cases of COVID-19 due to a shortage of hospital beds for people with severe cases, plus shortages of medicines and limited human resources.

Busy triage point outside the Emergency Department at the Christian Medial College, Vellore, Tamil Nadu, India © Ms Priyanka Gautam, Christian Medical College, Vellore, India

In a study published 21 March in Clinical Infectious Diseases, the PRIORITISE study team report the development and validation of three clinical prediction models that could help identify patients presenting with moderate Covid-19 who could safely be managed in the community. Identification of patients suitable for outpatient management could help decompress and protect health systems during current and future spikes in infections, especially in locations where capacity for inpatient monitoring is limited. The models, which contain three easily ascertainable clinical parameters (age, sex, SpO2) and one biomarker (IL-6, NLR or suPAR) measurable using a point-of-care test, would be readily implementable in many LMIC settings. The study was a collaboration between MSF India and MORU, in partnership with the teams at CMC Vellore and AIIMS Patna, supported by FIND, and funded by MSF and the Wellcome Trust.

The PRIORITISE team would like to hear from groups interested in collaborating to further validate the findings. This is important before the models can be recommended for use. Ideally this would happen before another surge in infections, so partners who already have baseline clinical data and bio-banked plasma from patients with moderate Covid-19, alongside data on clinical outcomes over the next 14-28 days, are encouraged to get in touch.

Please share and, if interested, kindly contact Arjun Chandna or Sakib Burza

Read the full publication 'Facilitating safe discharge through predicting disease progression in moderate COVID-19: a prospective cohort study to develop and validate a clinical prediction model in resource-limited settings' on the Clinical Infectious Diseases website

- Text courtesy of Arjun Chandna, on behalf of the PRIORITISE team, with thanks to Ms. Priyanka Gautam, Christian Medical College, Vellore, India for the photo.

Similar stories

New antibiotic combination speeds recovery from severe scrub typhus, which infects 1 million people per year

Treating patients ill with severe scrub typhus – a life-threatening infection that kills tens of thousands of people a year - with a combination of intravenous antibiotics doxycycline and azithromycin is significantly more effective than the current monotherapy of using either drug alone, say researchers in a study published in the New England Journal of Medicine (NEJM).

Watch our webinar - Radical cure of vivax malaria: can we do better?

The three presentations and expert discussion by Dr Rob Commons, Dr Alison Roth and Dr James Watson, chaired by Professor Sir Nicholas White (Mahidol Oxford Research Unit) and Dr Chau Nguyen Hoang (Oxford University Clinical Research Unit), are now available.

Study supports evidence ivermectin not effective to treat COVID-19

21 Feb 2023 Oxford UK - High doses of the drug ivermectin, controversially recommended by some high-profile political and media figures during the COVID-19 pandemic, is ineffective at treating the COVID-19 virus, say University of Oxford-affiliated researchers in a study published today in eLife.

Phase II Malaria vaccine trial begins in Thailand

The Mahidol Oxford Tropical Medicine Research Unit (MORU) has begun a Phase II trial to demonstrate that R21/matrix M is well-tolerated and immunogenic when administered with the antimalarial drug combination.

Pilot study detects diverse DNA in ingredients of falsified tablets

A recent multidisciplinary pilot study, originating from LOMWRU and the Medicine Quality Research Group of IDDO and MORU, investigated whether bacterial, plant, fungal and animal DNA in the ingredients and from the environment (eDNA) could be detected from falsified (aka counterfeit) tablets.

Ricardo Aguas awarded Associate Professorship

We are delighted to announce that Ricardo Aguas has been awarded the Associate Professor title, in recognition of his achievements, contribution to teaching, and contribution to the general work of the Nuffield Department of Medicine.